Skip to main content
SpringerLink
Log in
Book cover

AIDS in Africa pp 373–386Cite as

Tuberculosis

  • Chapter

  • 219 Accesses

Conclusion

TB is a disease that threatens all persons, regardless of immune status. Increased rates ofTB disease, combined with its airborne transmission, pose a public health threat to all persons and not only to those with HIV infection. Unfortunately, a large burden of the world’s TB morbidity and mortality has been and will continue to be borne by those with HIV infection. The HIV pandemic has changed the natural history, clinical manifestations, and paradigms for controlling TB in individuals, institutions and the general population, and aggressive efforts for its control are desperately needed. In Africa, HIV infection and TB cases are integrally linked. Thus, prevention and control efforts aimed at each disease must take the other into consideration. This may be best accomplished by integrating TB and AIDS activities in African nations. The scope of TB control should be expanded to include broad case finding and wide-scale implementation of DOT to guarantee effective treatment of all TB patients. Among those with HIV infection, latent TB infections must be treated; measures to prevent HIV transmission must be implemented; and HAART must be provided. Only when these measures are in place, can there be both decreased morbidity and mortality in persons coinfected with HIV and M. tuberculosis, and effective control of TB in Africa.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. UNAIDS. Report on the global HIV/AIDS epidemic. Geneva: UNAIDS, June 2000.

    Google Scholar 

  2. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med, 1999;340:367–373.

    Article  PubMed  CAS  Google Scholar 

  3. Harries AD, Hargreaves NJ, Kemp J, et al. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet, 2001;357:1519–1523.

    Article  PubMed  CAS  Google Scholar 

  4. Kubica GP, Wayne LG. The Mycobacteria: A Source Book. New York: Marcel Dekker, 1984: 38–41.

    Google Scholar 

  5. Hanna BA. Diagnosis of tuberculosis by microbiologic techniques. In: Rom W, Garay S, eds. Tuberculosis, 1st ed. Boston: Little, Brown and Company, 1996:149–159.

    Google Scholar 

  6. Riley RL. Airborne infection. Am J Med, 1974;57:466–475.

    Article  PubMed  CAS  Google Scholar 

  7. Curtis A, Ridzon R, Ferry J, et al. Extensive transmission of M. tuberculosis from a child. N Engl J Med, 1999;341:1491–1495.

    Article  PubMed  CAS  Google Scholar 

  8. Cauthen GM, Dooley SW, Onorato IM, et al. Transmission of Mycobacterium tuberculosis from tuberculosis patients with HIV infection or AIDS. Am J Epidemiol, 1996;144;69–77.

    PubMed  CAS  Google Scholar 

  9. Dye C, Scheele S, Dolin P, et al. Consensus Statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA, 1999;282:677–686.

    PubMed  CAS  Google Scholar 

  10. Styblo K. The global aspect of tuberculosis and HIV infection. Bull Int Union Tuberc Lung Dis, 1990;65:28–32.

    PubMed  CAS  Google Scholar 

  11. World Health Organization. Global Tuberculosis Control, WHO Report 2001. WHO/TB/2001.287. Geneva: World Health Organization, 2001.

    Google Scholar 

  12. Report on the Global HIV/AIDS Epidemic. UNAIDS/00.13E. UNAIDS: Geneva, 2000.

    Google Scholar 

  13. Harries AD, Maher D. TB/HIV: A Clinical Manual. Geneva: World Health Organization, 1996;126–127.

    Google Scholar 

  14. Maher D, Chaulet P, Spinaci S, et al. Treatment of tuberculosis: guidelines for national programmes, 2nd ed. Geneva: World Health Organization, 1997.

    Google Scholar 

  15. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. AIDS, 1993;7:1569–1579.

    PubMed  CAS  Google Scholar 

  16. Whalen C, Horsburgh CR, Hom D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med, 1995;151:129–135.

    PubMed  CAS  Google Scholar 

  17. Whalen C, Okwera A, Johnson J, et al. Predictors of survival in HIV-infected patients with pulmonary tuberculosis. Makerere University-Case Western Reserve University Research Collaboration. Am J Respir Crit Care Med, 1996;153:1977–1981.

    PubMed  CAS  Google Scholar 

  18. World Health Organization. Global Tuberculosis. Control. WHO Report 2000. WHO/CDS/TB/2000. 275. Geneva: World Health Organization, 2000.

    Google Scholar 

  19. Raviglione MC, Harries AD, Msiska R, et al. Tuberculosis and HIV: current status in Africa. AIDS, 1997;1l(suppl B):S115.

    Google Scholar 

  20. Kenyon TA, Mwasekaga MJ, Huebner R, et al. Low levels of drug-resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis, 1999;3:4–11.

    PubMed  CAS  Google Scholar 

  21. Eriki PO, Okwera A, Aisu T, et al. The influence of human immunodeficiency virus infection on tuberculosis in Kampala, Uganda. Am Rev Respir Dis, 1991;143:185–187.

    PubMed  CAS  Google Scholar 

  22. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR, 2000;49(No. RR-6):7–10.

    Google Scholar 

  23. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR, 1998;47(RR-20):1–58.

    Google Scholar 

  24. Whalen CC, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS, 2000;14:1219–1228.

    PubMed  CAS  Google Scholar 

  25. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med, 1989;320:545–550.

    Article  PubMed  CAS  Google Scholar 

  26. Perlman DC, El-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related suppression. Clin Infect Dis, 1997;25:242–246.

    PubMed  CAS  Google Scholar 

  27. Wallis RS, Vjecha M, Amir-Tahmasseb M, et al. Influence of tuberculosis on human immunodeficiency virus (HIV-1); enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis. J Infect Dis, 1993;167:43–48.

    PubMed  CAS  Google Scholar 

  28. Vanham G, Edmonds K, Qing L, et al. Generalized immune activation in pulmonary tuberculosis: coactivation with HIV infection. Clin Exp Immunol, 1996;103:30–34.

    Article  PubMed  CAS  Google Scholar 

  29. Badri M, Ehrlich R, Wood R, et al. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis, 2001;5:225–232.

    PubMed  CAS  Google Scholar 

  30. Theuer CP, Hopewell PC, Elias D, et al. Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis, 1990;162:8–12.

    PubMed  CAS  Google Scholar 

  31. Elliott AM, Namaambo K, Allen BW, et al. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuberc Lung Dis, 1993;74:191–194.

    CAS  Google Scholar 

  32. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg, 1993;96:1–11.

    PubMed  CAS  Google Scholar 

  33. Thonell L, Pendle S, Sacks L. Clinical and radiologic features of South African patients with tuberculomas of the brain. Clin Infect Dis, 2000;31:619–620.

    Article  PubMed  CAS  Google Scholar 

  34. Sassan-Morokro M, De Cock KM, Ackah A, et al. Tuberculosis and HIV infection in children in Abidjan, Cote d’Ivoire. Trans R Soc Trop Med Hyg, 1994;88:178–181.

    Article  PubMed  CAS  Google Scholar 

  35. Chintu C, Bhat G, Luo C, et al. Seroprevalence of human immunodeficiency virus type 1 infection in Zambian children with tuberculosis. Pediatr Infect Dis J, 1993; 12:499–504.

    PubMed  CAS  Google Scholar 

  36. Kiwanuka J, Graham SM, Coulter JB, et al. Diagnosis of pulmonary tuberculosis in children in an HIV-endemic area, Malawi. Annals of Tropical Paediatrics, 2001:21:5–14.

    Article  PubMed  CAS  Google Scholar 

  37. Granich R, Binkin NJ, Jarvis WR, et al. Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. WHO/CDS/TB/99.269. Geneva: World Health Organization, 1999.

    Google Scholar 

  38. Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thiacetazone and rifampicincontaining regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet, 1994;344:1323–1328.

    Article  PubMed  CAS  Google Scholar 

  39. Perriens JH, Colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with “standard“ chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis, 1991;144:750–755.

    PubMed  CAS  Google Scholar 

  40. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet, 1993;342:332–337.

    Article  PubMed  CAS  Google Scholar 

  41. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg, 1995;89:78–82.

    Article  PubMed  CAS  Google Scholar 

  42. Pulido F, Pena JM, Rubio R, et al. Relapse of tuberculosis after treatment in human immunodefiency virus-infected patients. Arch Intern Med, 1997; 157:227–232.

    Article  PubMed  CAS  Google Scholar 

  43. Johnson JL, Okwere A, Nsubuga P, et al. Efficacy of unsupervised 8-month rifampicin-containing regimen for treatment of pulmonary tuberculosis in HIV-infected adults. Int J Tuberc and Lung Dis, 2000;4:1032–1040.

    CAS  Google Scholar 

  44. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med, 1993;329:784–791. [erratum appears in N Engl J Med 1993 Nov 4;329(19):1435]

    Article  PubMed  CAS  Google Scholar 

  45. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS, 2001;15:143–152.

    Article  PubMed  CAS  Google Scholar 

  46. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR, 2000;49:185–189.

    Google Scholar 

  47. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med, 1998;158:157–161.

    PubMed  CAS  Google Scholar 

  48. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med, 1997;337:801–808.

    Article  PubMed  CAS  Google Scholar 

  49. Hawken MP, Meme HK, Elliot LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-infected adults: results of a randomized controlled trial. AIDS, 1997;11:875–882.

    Article  PubMed  CAS  Google Scholar 

  50. Mwinga AG, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS, 1998;12:2447–2457.

    Article  PubMed  CAS  Google Scholar 

  51. Gordin FM, Mats JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med, 1997;5:315–320.

    Google Scholar 

  52. Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on the incidence of active tuberculosis and progression of HIV infection. Lancet, 1993;243:268–272.

    Google Scholar 

  53. World Health Organization. Preventive therapy against tuberculosis in people living with HIV. Weekly Epidemiological Record, 1999;74:385–400.

    Google Scholar 

  54. Rivero A, Marquez M, Santos J, et al. High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B. Clin Infect Dis, 2001;32:159–161.

    Article  PubMed  CAS  Google Scholar 

  55. Sacks LV, Pendle S, Orlovic D, et al. A comparison of outbreak-and nonoutbreak-related multidrug-resistant tuberculosis among human immunodeficiency virus-infected patients in a South African hospital. Clin Infect Dis, 1999;29:96–101.

    Article  PubMed  CAS  Google Scholar 

  56. Harries AD, Maher D, Nunn P. Practical and affordable measures for the protection of health care workers from tuberculosis in low-income countries. Bull WHO, 1997;75:477–489.

    PubMed  CAS  Google Scholar 

  57. Espinal MA, Lazlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med, 2001;344:1294–1303.

    Article  PubMed  CAS  Google Scholar 

  58. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis treatment outcomes in 6 countries. JAMA, 2000;283:2537–2545.

    Article  PubMed  CAS  Google Scholar 

  59. World Health Organization. Guidelines for establishing DOTS-plus pilot projects for the management of MDR-TB. 2000; WHO/CDS/TB/2000:279.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

    Renée Ridzon

  2. Faculty of Medicine, Makerere University, Kampala, Uganda

    Harriet Mayanja-Kizza

Authors
  1. Renée Ridzon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harriet Mayanja-Kizza
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Harvard AIDS Institute Mary Woodard Lasker Professor of Health Sciences Harvard University, Boston, Massachusetts, USA

    Max Essex DVM, PhD (Chairman) & Richard G. Marlink MD (Senior Research and Executive Director) (Chairman) &  (Senior Research and Executive Director)

  2. Laboratory of Bacteriology and Virology CHU Le Dantec, Université Cheikh Anta Diop, Dakar, Senegal

    Souleymane Mboup PharmD, PhD (Professor of Microbiology) (Professor of Microbiology)

  3. Department of Immunology and Infectious Diseases and the Harvard AIDS Institute, Harvard School of Public Health, Boston, Massachusetts, USA

    Phyllis J. Kanki DVM, DSc (Professor of Immunology and Infectious Diseases) & Molly Holme (Professor of Immunology and Infectious Diseases) & 

  4. Department of Nursing Education University of Botswana, Gaborone, Botswana

    Sheila D. Tlou PhD (Associate Professor) (Associate Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Kluwer Academic Publishers

About this chapter

Cite this chapter

Ridzon, R., Mayanja-Kizza, H. (2002). Tuberculosis. In: Essex, M., Mboup, S., Kanki, P.J., Marlink, R.G., Tlou, S.D., Holme, M. (eds) AIDS in Africa. Springer, Boston, MA. https://doi.org/10.1007/0-306-47817-X_22

Download citation

  • DOI: https://doi.org/10.1007/0-306-47817-X_22

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-46699-1

  • Online ISBN: 978-0-306-47817-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation